Onxeo is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Our approach is based upon a unique mechanism of action of decoy agonist interfering with DNA Damage Response. We focus on bringing first-in-class and disruptive compounds from translational research to proof-of-concept in man in cancer indications with high unmet needs.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.